Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trials with CMV-specific T cells.

K S Peggs1, S Mackinnon

  • 1Department of Haematology, University College Hospital, London, UK.

Cytotherapy
|April 16, 2002
PubMed
Summary

Reactivating cytomegalovirus (CMV) after stem cell transplants is a challenge. New T-cell therapies show promise for restoring anti-CMV immunity with low risks of graft-versus-host disease and demonstrated antiviral activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.

British journal of haematology·2021
Same author

ENT trainees' experience of redeployment during the coronavirus disease 2019 pandemic: a qualitative study.

The Journal of laryngology and otology·2021
Same author

Absence of damaging effects of stem cell donation in unrelated donors assessed by FISH and gene variance screening.

Bone marrow transplantation·2020
Same author

Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants.

Bone marrow transplantation·2017
Same author

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.

Bone marrow transplantation·2017

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Virology

Background:

  • Cytomegalovirus (CMV) reactivation post-allogeneic hematopoietic stem cell transplantation (HSCT) causes significant morbidity.
  • Current surveillance and antiviral therapies have limitations.
  • Selective restoration of anti-CMV cellular immunity is a promising alternative.

Purpose of the Study:

  • To review advancements in generating CMV-specific T cells for adoptive therapy.
  • To discuss challenges and strategies for clinical implementation and monitoring.
  • To present preliminary data from newer clinical trials.

Main Methods:

  • Review of lessons learned from Epstein-Barr virus (EBV) studies.
  • Utilizing various antigen-presenting cells (monocytes, dendritic cells, B-lymphoblastoid cell lines).
  • Employing exogenous antigen pulsing or endogenous antigen processing via viral vectors.

Main Results:

  • Multiple systems for culturing CMV-specific T cells have been characterized.
  • T cells targeting CMV antigens (e.g., pp65) can be generated.
  • Early clinical trials indicate feasibility and potential efficacy.

Conclusions:

  • Newer generation CMV-specific T-cell products can be administered with low risk of graft-versus-host disease.
  • Demonstrated antiviral activity following infusion.
  • Clinical trials are ongoing, with preliminary data suggesting therapeutic potential.

Related Experiment Videos